TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16357081

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 10)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (n = 6)
Number of subjects: 16
Study: 12791192

Group type: EXPERIMENTAL
Intervention: Prostant
Number of subjects: 119
Study: 10793541

Group type: EXPERIMENTAL
Intervention: 2% carteolol hydrochloride (30 microliters, twice daily for 7 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (30 microliters)
Number of subjects: 10
Study: 8712390

Group type: EXPERIMENTAL
Intervention: 50-Hz tetanic stimuli
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 100-Hz tetanic stimuli
Number of subjects: 22

Group type: COMPARATOR
Intervention: neostigmine (40 micrograms/kg)
Number of subjects: 22
Study: 1857658

Group type: EXPERIMENTAL
Intervention: Iontophoresis with anesthetic
Number of subjects: 10

Group type: COMPARATOR
Intervention: Iontophoresis with placebo
Number of subjects: 10
Study: 6354728

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30091121

Group type: EXPERIMENTAL
Intervention: Brief personalized informational video (3-5 min)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Standard care (legislatively required letter about MBD)
Number of subjects: 459
Study: 30400832

Group type: EXPERIMENTAL
Intervention: LiFE (individually delivered lifestyle-integrated functional exercise program)
Number of subjects: 300

Group type: COMPARATOR
Intervention: gLiFE (group-delivered lifestyle-integrated functional exercise program)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: LiFE
Number of subjects: 300

Group type: COMPARATOR
Intervention: gLiFE
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: LiFE and gLiFE
Number of subjects: 300
Study: 27008904

Group type: EXPERIMENTAL
Intervention: Variable light (concentration and soothing programs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard lighting
Number of subjects: 30
Study: 23780902

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) during recovery periods of Repeated Sprint Ability (RSA) tests
Number of subjects: 17
Study: 21293243

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 6) plus Paclitaxel (200 mg/m²) on day 1 (CP)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m²) plus Vinorelbine (25 mg/m²) on days 1 and 8 (GV)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Carboplatin plus Paclitaxel (CP)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Gemcitabine plus Vinorelbine (GV)
Number of subjects: 89
Study: 19719526

Group type: EXPERIMENTAL
Intervention: Urgotul™
Number of subjects: 25

Group type: COMPARATOR
Intervention: Tulle-gras (TG)
Number of subjects: 25
Study: 17945036

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m(2) over 100 minutes on days 1 and 15 in combination with oxaliplatin 100 mg/m(2) over 2 hours on days 2 and 16, every 4 weeks.
Number of subjects: 10
Study: 15094442

Group type: EXPERIMENTAL
Intervention: 131I ablation after lobectomy
Number of subjects: 225

Group type: COMPARATOR
Intervention: 131I ablation after total thyroidectomy
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Pre-ablative 131I neck uptake
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Whole-body 131I burden 2 days post-therapy
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Biological half-life of radioiodine
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Serum thyroglobulin levels at 3 months post-ablation
Number of subjects: 225
Study: 11761092

Group type: EXPERIMENTAL
Intervention: Separate management of suction blood using the Avant D903 oxygenator (n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group with suction blood filtered and redirected immediately (n = 10)
Number of subjects: 21
Study: 9737282

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented enteral nutrition
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (balanced, isonitrogenous, isocaloric enteral feeding)
Number of subjects: 72
Study: 7827294

Group type: EXPERIMENTAL
Intervention: Simvastatin (n = 10)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bezafibrate (n = 7)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17
Study: 3050570

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 131

Group type: COMPARATOR
Intervention: Behavioral training alone
Number of subjects: 131
Study: 8466265

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEpo) 50 to 150 U administered subcutaneously twice a week from 7 days of age until discharge
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEpo)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 104378

Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 26
Study: 31595391

Group type: EXPERIMENTAL
Intervention: Preemptive analgesia of celecoxib
Number of subjects: 100

Group type: COMPARATOR
Intervention: Postoperative analgesia of celecoxib
Number of subjects: 100
Study: 31215467

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amine fluoride (AmF) dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoridated bioactive glass dentifrice
Number of subjects: 0
Study: 27418422

Group type: EXPERIMENTAL
Intervention: Three-dimensional virtual reality vestibular rehabilitation (modified Cawthorne-Cooksey exercises: eye, head, extension, and coordination exercises) performed in six training sessions over 4 weeks.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 70
Study: 26435200

Group type: EXPERIMENTAL
Intervention: Conjoint analysis intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 23398142

Group type: EXPERIMENTAL
Intervention: Early intervention group based on the 7 Steps of the Baby Friendly Community Initiative (BFCI)
Number of subjects: 1781

Group type: COMPARATOR
Intervention: Late intervention group based on the 7 Steps of the Baby Friendly Community Initiative (BFCI)
Number of subjects: 1781
Study: 21557378

Group type: EXPERIMENTAL
Intervention: Medication Adherence Questionnaire (MAQ)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Compliance Rating Scale (CRS)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Drug Attitude Inventory (DAI)
Number of subjects: 119
Study: 19464612

Group type: EXPERIMENTAL
Intervention: 50% N(2)O in O(2) for three minutes
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 50% N(2)O in O(2) for 5 minutes
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 70% N(2)O in O(2) for three minutes
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 70% N(2)O in O(2) for 5 minutes
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study: 17712244

Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg/day for the first week and 20 mg/day thereafter)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Fluoxetine and Placebo (CDRS‐R and MADRS)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CDRS‐R
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: MADRS
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CDRS‐R and MADRS
Number of subjects: 96
Study: 14733787

Group type: EXPERIMENTAL
Intervention: Intra-amniotic administration of pulmonary surfactant (PS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study: 11395840

Group type: EXPERIMENTAL
Intervention: Forced warm air blanket
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cotton blanket
Number of subjects: 100
Study: 9951629

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7810285

Group type: EXPERIMENTAL
Intervention: AZT therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not receiving AZT)
Number of subjects: 10
Study: 2843722

Group type: EXPERIMENTAL
Intervention: Oral testosterone (200 mg t.i.d.)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 31308062

Group type: EXPERIMENTAL
Intervention: Monalizumab 10 mg/kg i.v. every 2 weeks
Number of subjects: 58
Study: 27866841

Group type: EXPERIMENTAL
Intervention: Thai Yoga (TY)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Tai Chi (TC)
Number of subjects: 39
Study: 26129831

Group type: EXPERIMENTAL
Intervention: Mindlight (experimental condition)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Triple Town (control condition)
Number of subjects: 120
Study: 24238518

Group type: EXPERIMENTAL
Intervention: 0.075% ropivacaine
Number of subjects: 200

Group type: COMPARATOR
Intervention: 0.1% ropivacaine
Number of subjects: 200
Study: 21632509

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin with PF-3512676 (0.2 mg/kg subcutaneous on days 8 and 15)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin alone (control arm)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin with PF-3512676
Number of subjects: 828
Study: 19646346

Group type: EXPERIMENTAL
Intervention: ANCA against PR3
Number of subjects: 44

Group type: COMPARATOR
Intervention: ANCA against deglycosylated recombinant variants of PR3
Number of subjects: 44
Study: 16393305

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v (10^11 CFU/day) for 2 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (without L. plantarum 299v)
Number of subjects: 29
Study: 15341559

Group type: EXPERIMENTAL
Intervention: Calcium (500 mg/d) and vitamin D (400-600 IU/d) supplements
Number of subjects: 2565
Study: 11146898

Group type: EXPERIMENTAL
Intervention: Twice-a-day administration of interferon-alpha
Number of subjects: 47

Group type: COMPARATOR
Intervention: Once-a-day administration of interferon-alpha
Number of subjects: 47
Study: 8856002

Group type: EXPERIMENTAL
Intervention: Fluoxetine, 20 mg daily
Number of subjects: 671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 671

Group type: COMPARATOR
Intervention: Fluoxetine and Placebo
Number of subjects: 671
Study: 1627944

Group type: EXPERIMENTAL
Intervention: wuzi yanzong solution (WYS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 6697796

Group type: EXPERIMENTAL
Intervention: Deep-breathing exercises
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Deep-breathing exercises with vibrations
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 12
Study: 29370992

Group type: COMPARATOR
Intervention: Nivolumab monotherapy (3 mg/kg every 2 weeks)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses, then nivolumab monotherapy)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Nivolumab monotherapy
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 85
Study: 29272007

Group type: EXPERIMENTAL
Intervention: Training with ice stimulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine examinations, graded swallowing training, radio frequency electrotherapy, acupuncture, dietary guidance, body position and compensation training
Number of subjects: 40
Study: 26282726

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg (D110)
Number of subjects: 14283

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg (D150)
Number of subjects: 14283

Group type: COMPARATOR
Intervention: Warfarin (W)
Number of subjects: 14283

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 14283
Study: 23971173

Group type: EXPERIMENTAL
Intervention: Pulmonary nodule management based on volumetry
Number of subjects: 0
Study: 20139920

Group type: EXPERIMENTAL
Intervention: Moxonidine (0.4 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg)
Number of subjects: 15
Study: 18264747

Group type: EXPERIMENTAL
Intervention: ACE-inhibitors, angiotensin receptor blockers (ARBs), and aldosterone antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irbesartan and spironolactone
Number of subjects: 0
Study: 16085437

Group type: EXPERIMENTAL
Intervention: IV paracetamol 2g
Number of subjects: 297

Group type: COMPARATOR
Intervention: IV paracetamol 1g
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 12823597

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a (40 kDa) 90 microg
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a (40 kDa) 180 microg
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a (40 kDa) 270 microg
Number of subjects: 194

Group type: COMPARATOR
Intervention: conventional interferon alpha‐2a 4.5 MIU
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: All peginterferon alpha‐2a (40 kDa) doses combined
Number of subjects: 194
Study: 10082229

Group type: EXPERIMENTAL
Intervention: alpha-methyl-para-tyrosine (AMPT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: promethazine (placebo)
Number of subjects: 10
Study: 7569092

Group type: EXPERIMENTAL
Intervention: Asymmetric screen-film systems (InSight HC and High Light GCA)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mechanical homogenized (Tau-Gil Homogenized)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional high-kilovoltage techniques
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High Light GCA system
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: InSight system
Number of subjects: 200
Study: 2327646

Group type: EXPERIMENTAL
Intervention: Respirgard II (smallest droplet size profile)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Acorn System 22 (largest droplet size profile)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Respirgard II with inspiratory baffle removed
Number of subjects: 9
Study: 6797778

Group type: EXPERIMENTAL
Intervention: Non-selective beta-blockade (pindolol, 15 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardio-selective blockade (metoprolol, 200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardio-selective blockade (acebutolol, 500 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (4 weeks treatment)
Number of subjects: 0
Study: 31823135

Group type: EXPERIMENTAL
Intervention: PBMT (Laser 100 mW, 808 nm, 159.24 J/cm2/point, 5 J/point)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PBMT + exoskeleton
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo + PBMT
Number of subjects: 15
Study: 31815658

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrates (PCC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Number of subjects: 50
Study: 27504889

Group type: EXPERIMENTAL
Intervention: SAGAT tool for assessing situational awareness (SA)
Number of subjects: 43
Study: 26522063

Group type: EXPERIMENTAL
Intervention: Rocker
Number of subjects: 62

Group type: COMPARATOR
Intervention: X-Stop
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 23715889

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid filler (Glytone 1, HA concentration: 14 mg/g)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Saline physiological solution (control)
Number of subjects: 55
Study: 21482607

Group type: EXPERIMENTAL
Intervention: Weekly healthy lifestyle group (intervention)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Monthly school-readiness group (control)
Number of subjects: 106
Study: 19652934

Group type: EXPERIMENTAL
Intervention: Amphotericin B lozengers
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 17292880

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Perhexiline pre-treatment with Nitroglycerin
Number of subjects: 39
Study: 15335126

Group type: EXPERIMENTAL
Intervention: Cancer Screening Office Systems (Cancer SOS) intervention
Number of subjects: 1196
Study: 11431176

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coadministration of Enalapril and Losartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coadministration of Enalapril and Losartan (doubled doses)
Number of subjects: 0
Study: 9478178

Group type: EXPERIMENTAL
Intervention: Oncology home care (OHC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard home care
Number of subjects: 46

Group type: COMPARATOR
Intervention: Office care control
Number of subjects: 46
Study: 9621474

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 intracervical (PGE2 IC) gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin infusion and artificial rupture of membrane (ARM)
Number of subjects: 100
Study: 1789814

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg b.i.d.
Number of subjects: 0
Study: 7014318

Group type: EXPERIMENTAL
Intervention: Immediate endoscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Next-day endoscopy
Number of subjects: 100
Study: 31920057

Group type: EXPERIMENTAL
Intervention: Propolis solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alkaline peroxide
Number of subjects: 30
Study: 28596379

Group type: EXPERIMENTAL
Intervention: Sustained Inflation (SI)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Positive Pressure Ventilation (PPV)
Number of subjects: 162
Study: 25123978

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 1079

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1079
Study: 23975566

Group type: EXPERIMENTAL
Intervention: OptiScope
Number of subjects: 400

Group type: COMPARATOR
Intervention: Macintosh
Number of subjects: 400
Study: 22224109

Group type: EXPERIMENTAL
Intervention: Sodium profile 3 and ultra filtration profile 3
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cold dialysate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of sodium profile 3, ultra filtration profile 3, and cold dialysate
Number of subjects: 24
Study: 19033829

Group type: EXPERIMENTAL
Intervention: Web-based family treatment program
Number of subjects: 9
Study: 17146317

Group type: EXPERIMENTAL
Intervention: Vitamin and mineral supplementation (Vm group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (Pl group)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups (Vm and Pl)
Number of subjects: 22
Study: 12876635

Group type: EXPERIMENTAL
Intervention: Oral estradiol-1beta combined with micronised progesterone (n=63)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol-1beta combined with micronised progesterone (n=68)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo (n=65)
Number of subjects: 196
Study: 10981839

Group type: EXPERIMENTAL
Intervention: Thinking about mortality
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not thinking about mortality
Number of subjects: 0
Study: 8825538

Group type: EXPERIMENTAL
Intervention: Doxacurium 0.05 mg.kg‐1 (Group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Doxacurium 0.075 mg.kg‐1 (Group 2)
Number of subjects: 20
Study: 1909485

Group type: EXPERIMENTAL
Intervention: Lisuride alone (1.43 +/- 0.10 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lisuride plus selegiline (10 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo plus lisuride
Number of subjects: 20
Study: 6195911

Group type: EXPERIMENTAL
Intervention: Propranolol, 40 mg every 8 hours
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Acebutolol, 300 mg every 8 hours
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31934845

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation plus usual care
Number of subjects: 449

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 449
Study: 30865291

Group type: EXPERIMENTAL
Intervention: Newly forming bone graft (NFBG) and coronally advanced flap (CAF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG) and CAF (control)
Number of subjects: 0
Study: 28952704

Group type: EXPERIMENTAL
Intervention: Combination therapy with 5-reductase inhibitors and blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24438381

Group type: EXPERIMENTAL
Intervention: Basic version of the web-based computer-tailored nutrition education intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plus version of the web-based computer-tailored nutrition education intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic nutrition information control condition
Number of subjects: 0
Study: 22926322

Group type: EXPERIMENTAL
Intervention: Experimental multilevel intervention designed to improve quality of care and resident outcomes
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Quality improvement methods and activities
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Leadership commitment to communication and active participation
Number of subjects: 29
Study: 19192047

Group type: EXPERIMENTAL
Intervention: Burning Mouth Syndrome (BMS) patients
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Menopausal or postmenopausal women with BMS
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: BMS patients
Number of subjects: 87
Study: 17496655

Group type: EXPERIMENTAL
Intervention: Bilateral cochlear implants
Number of subjects: 7
Study: 15097238

Group type: EXPERIMENTAL
Intervention: Inner wall tracking using a new prototype 'wall tracking' system
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Inner wall tracking
Number of subjects: 39

Group type: COMPARATOR
Intervention: Wall Track System (WTS)
Number of subjects: 39